SLGL (Sol-Gel Technologies) Other Current Receivables: $0.00 Mil (As of Mar. 2026)


SLGL Sol-Gel Technologies Ltd SLGL
55 GF Score
Price $71.74
GF Value $65.54
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Other Current Receivables?

Sol-Gel Technologies SLGL -0.88% 55 Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates SLGL with a GF Score™ of 55/100 and a GF Value™ of $65.54 (Fairly Valued). The stock has 2 warning signs investors should review.

Sol-Gel Technologies's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Sol-Gel Technologies Other Current Receivables Related Terms

Sol-Gel Technologies Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Sol-Gel Technologies's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sol-Gel Technologies Other Current Receivables Chart

Sol-Gel Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 7.86 0.00 0.00 0.00

Sol-Gel Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SLGL
55GF Score
Sol-Gel Technologies Ltd SLGL
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sol-Gel Technologies Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Sol-Gel Technologies (SLGL) has a Other Current Receivables of $0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sol-Gel Technologies and its competitors.
Is Sol-Gel Technologies' Other Current Receivables too high?
Sol-Gel Technologies' current Other Current Receivables is $0.00 Mil. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Other Current Receivables compare to AVXL and FATE?
Sol-Gel Technologies' Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Fairly Valued. The stock's GF Value™ is $65.54, compared to a current price of $71.74 — trading 9.5% above its estimated fair value. The current Other Current Receivables is $0.00 Mil. Sol-Gel Technologies' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $71.74 is trading 9.5% above its estimated GF Value™ of $65.54. GuruFocus considers Sol-Gel Technologies to be Fairly Valued.

Key valuation signals for SLGL:

  • Other Current Receivables: $0.00 Mil
  • GF Value™: $65.54 vs. price of $71.74 (9.5% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges 4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score

Get the complete analysis for SLGL

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.74
Price
$65.54
GF Value